No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ACLX241220C120000
- 0.50
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
0.50Open0.50Pre Close0 Volume536 Open Interest120.00Strike Price0.00Turnover0.00%IV59.52%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma151.08Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Buy Rating for Arcellx Inc. Based on Promising Efficacy and Safety of BCMA CAR-T Therapy in IMMagine-1 Study
Morgan Stanley Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $111
Truist Financial Initiates Arcellx(ACLX.US) With Buy Rating
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $111 to $122
Arcellx Inc (ACLX) Gets a Buy From Truist Financial
Promising Outlook for Arcellx Inc: Anito-cel Therapy Positioned as a Safer Alternative With Strong Market Potential